Floatz logo

ER-176

LPA

Mayo ClinicSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the LPA cohort.

Asset / SponsorPhaseRating
PITTSBURGH COMPOUND B UNLABELLED
Mayo Clinic
Phase 1CC
FLORTAUCIPIR
Mayo Clinic
D
FLORTAUCIPIR
University of Pennsylvania
D
FLORTAUCIPIR
Mayo Clinic
N/AD

Same molecule, other indications

ER-176 is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
55 / 100
View asset →
Alzheimer diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
demyelinating diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →